About Signal Pharmaceuticals
Signal Pharmaceuticals is a Healthcare company based in San Diego (United States) founded in 1993, and was acquired by Celgene in June 2000. Small molecule drugs regulating disease-associated genes are developed. Signal Pharmaceuticals has raised $12 million across 2 funding rounds from investors including New York Life Insurance, Celgene and Robertson Stephens Partners. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Services and Drug Discovery. Its competitors include eGenesis, Beam Therapeutics and Korro Bio; 3 of its 3 listed competitors have raised funding.
Company details
Signal Pharmaceuticals was founded in 1993 in San Diego, United States, within the biotechnology sector. Research and development efforts are directed toward small molecule drugs that modulate disease-related genes. Advanced cellular, molecular, and genomic technologies are utilized to map gene-regulating pathways and identify proprietary targets for gene activation or deactivation. Partnerships with pharmaceutical companies are formed to advance drug discovery for disease-associated genes.
- Headquarters San Diego, United States
- Stage Acquired
- SectorsHealthcare
- Website signalpharm.com
- Social LinkedIn
- Acquired by Celgene (Jun 2000)
- Total Equity Funding$12M (USD)
in 2 rounds
- Latest Funding Round$12M (USD), Series E
Sep 1997
- InvestorsNew York Life Insurance
& 5 more
- Acquired byCelgene
(Jun 2000)
Funding Insights of Signal Pharmaceuticals
Signal Pharmaceuticals has successfully raised a total of $12M across 2 strategic funding rounds. The most recent funding activity was a Series E round of $12 million completed in September 1997. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $12M
- Total Rounds 2
- Last Round Series E β $12M
- Investors Count 5
All 2 funding rounds of Signal Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 1997 | $12M | Series E | β | β | |
| Jun 1993 | Series D | β | β |
6 investors in total: 6 institutional.
Investors in Signal Pharmaceuticals
Signal Pharmaceuticals has secured backing from 6 investors, including institutional and venture fund investors. Prominent investors backing the company include New York Life Insurance, Celgene and Robertson Stephens Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital firm focused on tech sectors | venrock.com | Palo Alto, United States | ||
Global financial advisory services are provided by the firm. | lehman.com | New York, United States | ||
Mutual life insurance and asset management services are provided. | 1845 | newyorklife.com | New York, United States | |
Wealth management firm | 1978 | rscapital.com | San Francisco, United States | |
R&D company focused on manufacturing of drugs for multiple therapeutic areas | 1997 | serono.com | Geneva, Switzerland | |
Therapies for cancer and inflammatory diseases are developed. | 1986 | celgene.com | Summit, United States |
Investor details for Signal Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Signal Pharmaceuticals
4 dated milestones of Signal Pharmaceuticals across 7 years, from founding to its latest funding, stage changes and deals.
- Founded Signal Pharmaceuticals is founded.
- Funding First funding round.
- Funding Latest funding round, Series E, of $12.0M.
- Exit Acquired by Celgene.
Competitors of Signal Pharmaceuticals
Signal Pharmaceuticals has 3 listed competitors in our database, 3 of them funded. They include eGenesis, Beam Therapeutics and Korro Bio.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| egenesisbio.com | 2015 | Cambridge, United States | $481.42M | 94 | Gene transplantation platform for humanizing pig cells is developed. | |
| beamtx.com | 2017 | Cambridge, United States | $222M | 340 | Developer of gene therapy using CRISPR base editing to treat diseases | |
| korrobio.com | 2018 | Cambridge, United States | $4M | 77 | RNA-editing technologies are provided for precision medicine applications. |
Detailed competitors of Signal Pharmaceuticals
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Signal Pharmaceuticals (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Signal Pharmaceuticals
Complete news archive for Signal Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Signal Pharmaceuticals
Signal Pharmaceuticals was founded in 1993.
Signal Pharmaceuticals is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Signal Pharmaceuticals is a funded company, having raised a total of $12M across 2 funding rounds to date.
Signal Pharmaceuticals was founded in 1993 in San Diego, United States, within the biotechnology sector. Research and development efforts are directed toward small molecule drugs that modulate disease-related genes. Advanced cellular, molecular, and genomic technologies are utilized to map gene-regulating pathways and identify proprietary targets for gene activation or deactivation. Partnerships with pharmaceutical companies are formed to advance drug discovery for disease-associated genes.
Signal Pharmaceuticals's top competitors include eGenesis, Korro Bio and Beam Therapeutics.
Signal Pharmaceuticals has 6 investors. Key investors include New York Life Insurance, Celgene, Robertson Stephens Partners, Ares Serono, and Lehman Brothers.
Yes. Signal Pharmaceuticals was acquired by Celgene in June 2000.

